Holen Sie sich die Stockscreener-App
10.01
0.00%
0.00
Schlusskurs vom Vortag:
$10.01
Offen:
$10.01
24-Stunden-Volumen:
381.88K
Relative Volume:
18.57
Marktkapitalisierung:
$219.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
+0.00%
1M Leistung:
+32.81%
6M Leistung:
+20.48%
1J Leistung:
+0.00%
1-Tages-Spanne:
$10.01
$10.02
1-Wochen-Bereich:
$10.00
$10.02
52-Wochen-Spanne:
$10.00
$10.02
Translational Development Acquisition Corp Stock (TDAC) Company Profile
Firmenname
Translational Development Acquisition Corp
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie TDAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TDAC
Translational Development Acquisition Corp
|
10.01 | 219.29M | 0 | 0 | 0 | 0.00 |
|
LION
Lionsgate Studios Corp
|
8.31 | 2.40B | 3.13B | 50.80M | 555.00M | 0.1772 |
|
AACT
Ares Acquisition Corporation Ii
|
11.06 | 691.25M | 0 | 16.92M | -1.35M | 0.29 |
|
GCL
Gcl Global Holdings Ltd
|
3.77 | 475.87M | 0 | 0 | 0 | 0.00 |
|
ANSC
Agriculture Natural Solutions Acquisition Corp
|
10.55 | 454.97M | 0 | 1.30M | 0 | 0.0301 |
|
AAM
Aa Mission Acquisition Corp
|
10.17 | 447.22M | 0 | 0 | 0 | 0.00 |
Translational Development Acquisition Corp Stock (TDAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-09-21 | Eingeleitet | Northland Capital | Outperform |
Translational Development Acquisition Corp Aktie (TDAC) Neueste Nachrichten
Translational Development Acquisition Corp. Announces that the Separate Trading of its Class A Ordinary Shares and Warrants has Commenced - Yahoo Finance
Trident Acquisitions stock hits 52-week high of $10.08 - Investing.com
ImmuPharma (LON:IMM) Stock Price Up 9.3% – Here’s Why - Defense World
TDACU stock touches 52-week low at $10 amid market challenges - Investing.com
ICR, the Leading SPAC Communications and Advisory Firm, Publishes its Yearend 2024 SPAC Market Update & Outlook - Business Wire
Translational Development (TDACU) Raises $172.5M in Successful Nasdaq IPO, Begins Trading - StockTitan
Valink Therapeutics Appoints Biopharmaceutical Veteran Martin D. Williams as Chair of the Board of Directors and Names Scientific Advisory Board - Business Wire
(PDF) Measuring Translation Competence Acquisition - ResearchGate
NImmune Biopharma Announces R&D Collaboration with BioTherapeutics, Inc. to Advance the Next Wave of Inflammation and Immunology Precision Medicines - Business Wire
Novo Nordisk Expands Boston Area Research and Early Development - Genetic Engineering & Biotechnology News
Locks on Translation Initiation May Restrain Cancer - Genetic Engineering & Biotechnology News
FirstEnergy issues earnings report - 69News WFMZ-TV
Zura Bio Announces Appointment of Chief Scientific Officer - Business Wire
Special Purpose Acquisition Company (SPAC) News and Analysis - SPACInsider
Translation regulatory factor BZW1 regulates preimplantation embryo development and compaction by restricting global non-AUG Initiation - Nature.com
A Stone Capital-backed SPAC braves the blank check waters, looking to grab a $150M deal - Endpoints News
Gate Neurosciences Emerges from Stealth with a Portfolio of Next-Generation Therapies for Central Nervous System Diseases - Business Wire
Oak Hill Bio Appoints Tauhid Ali as First Chief Executive Officer - Business Wire
Quotient integrates drug substance into platform - Speciality Chemicals Magazine
Third Rock Ventures Announces Promotion of David Kaufman, M.D., Ph.D., to Partner - Business Wire
Research and Development grant cheat sheet - University of Sydney
A red blood cell disease meets a company with a plasma protein heritage - Nature.com
BioSpace Movers & Shakers, March 19 - BioSpace
BioSpace Movers & Shakers: MoMa Therapeutics, Cerevance, Glympse Bio and More - BioSpace
Horizon Therapeutics plc to Acquire Viela Bio, Inc. to Significantly Expand Development Pipeline and Grow Rare Disease Medicine Portfolio - Business Wire
Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development - The Lancet
Bristol-Myers Squibb's $74B acquisition of Juno parent Celgene puts Seattle biotech world on alert - GeekWire
Quotient Clinical’s second U.S. acquisition in a row: Charles River’s QS Pharma - Fierce Biotech
People - Nature.com
Finanzdaten der Translational Development Acquisition Corp-Aktie (TDAC)
Es liegen keine Finanzdaten für Translational Development Acquisition Corp (TDAC) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.00%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):